Midatech Pharma plc logo
Midatech Pharma plc MTP
report update icon

Quarterly report 2025-Q4
added 05-14-2026

Midatech Pharma plc Financial Ratios 2025-2011 | MTP

Annual Financial Ratios Midatech Pharma plc

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

- -250.7 -12.9 -0.2 -14.5 -0.0 -0.0 -1.1 -1.7 -2.1 -4.8 - - - -

P/S

- - 240.4 2.1 136.7 0.1 0.0 8.8 27.4 6.0 35.1 - - - -

EPS

-0.0 -0.0 -0.0 -1.6 - - - - -31 -56 -36 - - - -

EV (Enterprise Value)

-1.76 M 1.44 B 91.5 M 960 K 71.4 M -4.43 M 433 K 18.2 M 28.4 M 50.2 M 67.2 M 7.14 M 4.41 M - -

EBITDA per Share

- - -0.03 -1.81 -0.09 -2.51 K -1.23 K -19 -25.5 -40.5 -42.8 - - - -

EV/EBITDA

0.2 -156.7 -11.4 -0.1 - 0.8 0.6 -0.2 -1.6 -2.8 -4.3 - - - -

PEG

- -0.73 -0.01 -0.0 -0.01 -0.0 -0.0 0.01 0.03 -0.04 -0.13 - - - -

P/B

- 172.6 19.6 0.5 7.6 0.0 0.0 1.0 0.8 0.9 1.0 - - - -

P/CF

- -117.1 -13.4 -0.2 -13.2 -0.0 -0.0 -1.3 -2.1 -3.9 -5.0 - - - -

ROE %

-55.98 -68.84 -151.33 -242.13 - -330.29 -51.56 -88.81 -46.33 -44.10 -21.54 - - - -

ROA %

-35.12 -38.76 -67.15 -138.57 -42.28 -226.03 -32.64 -73.52 -32.63 -35.57 -15.77 - - - -

ROCE %

-71.74 -94.39 -161.15 -246.40 - -337.43 -44.86 -65.74 -32.49 -40.50 -23.51 - - - -

Current Ratio

2.7 2.3 1.8 2.3 5.2 3.2 2.7 5.8 3.4 2.4 2.2 - - - -

DSO

- - - - - - - - - 204.5 981.4 - - - -

DIO

- - - - - - - - - 40.6 2393.4 - - - -

DPO

- - - - - - - - - 162.3 11914.6 - - - -

Operating Cycle

- - - - - - - - - 245.0 3374.7 - - - -

Cash Conversion Cycle

- - - - - - - - - 82.8 -8539.9 - - - -

All numbers in GBP currency

Quarterly Financial Ratios Midatech Pharma plc

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.0001 -0.0002 -0.001 -0.001 -0.02 -4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - -0.03 -0.04 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-53.63 -148.98 -114.93 37.91 -151.33 67.33 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-24.52 -56.56 -37.42 23.68 -67.15 44.81 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-238.93 -328.34 -370.54 -40.27 -161.15 -74.73 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

2.7 4.4 2.3 4.5 1.8 3.0 - - - - 5.2 - - - 3.2 - - - 2.7 - - - 5.8 - - - 3.4 - - - 5.2 - - - 3.7 - - - - - - - - - - - - - - - - - - -

All numbers in GBP currency

Multiples are an important financial analysis tool for the company Midatech Pharma plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
- -6.00 % $ 238 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
- - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
- 0.38 % $ 12.9 M israelIsrael
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
- 2.07 % $ 34.4 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
- -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
- - $ 1.63 B usaUSA
Windtree Therapeutics Windtree Therapeutics
WINT
- - $ 26.8 M usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
- -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
- 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
- - $ 6.81 B britainBritain
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
- -7.58 % $ 264 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA